The Emmes Corporation today announced the completion of a pivotal clinical trial for a new product developed by IDx that could help in detecting diabetic retinopathy, the leading cause of blindness in the United States. IDx-DR is a fully autonomous AI-based diagnostic system that analyzes images of the retina for signs of diabetic retinopathy, providing instructions for follow-up care based on the level of disease detected. IDx-DR has been granted expedited review by the Food and Drug Administration.
{iframe}https://www.prnewswire.com/news-releases/emmes-and-idx-partner-using-artificial-intelligence-to-detect-diabetic-retinopathy-in-primary-care-300619758.html{/iframe}